The FDA gives an orphan drug designation to drug candidates that treat a disease that affects less than 200,000 persons in the United States.
The designation is designed to give financial incentives to drugmakers so that drugs for rare diseases will be developed. Those include:
- A 50% tax credit on clinical trial costs
- A break from paying Prescription Drug User Fee Act fees
- The all-important seven years of exclusive sales
Related Fool Articles
Recent Mentions on Fool.com
- 3 Biotech Stocks Bucking the Stock Market Crash
- Could Geron Corporation Be the Next Big Biotech Winner?
- Why Arrowhead Research Shares Are Rocketing 10% Higher Today
- BioMarin Pharmaceuticals: Lumpy Sales Strike Again
- Why Lexicon Pharmaceuticals' Stock Gained Over 50% Today
- The Blockbuster Potential of Biogen Inc's Pipeline